Perrigo Company plc (PRGO)
- PR Newswire
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
- PR Newswire
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).
- Insider Monkey
Here’s Why Perrigo Company PLC (PRGO) Stock Slumped in Q1
Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The portfolio had a 5.7% gain in the first quarter compared to an 8.2% return in the Russell Midcap Value Index. The Strategy underperformed in Financials and Industrials due […]
